Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CITIZENS FINANCIAL GROUP INC/RICFG · Entity 1913 | Director | February 14, 2019 | February 15, 2019 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | July 02, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CITIZENS FINANCIAL GROUP INC/RI
Report date February 14, 2019 · Filed February 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,993.604 |
Reported balance
After 2019-02-14 transaction · row 1
1 source rowRow 1 · 2019-02-14 · Grant · Acquired 30.91 · Balance 60,993.604 F1: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan.
REGENERON PHARMACEUTICALS, INC.
Report date July 02, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,303 |
Reported balance
After 2026-07-02 transaction · row 1
1 source rowRow 1 · 2026-07-02 · Sale · Disposed 200 · Balance 17,303 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F2: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.
F2: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $1,089.64 | $7,627.48 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 20 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,835 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F10 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on August 1, 2024 at prices ranging from $1,089.06 to $1,089.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $1,088.70 | $3,266.10 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 19 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,842 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F9 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on August 1, 2024 at prices ranging from $1,088.54 to $1,088.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $1,087.54 | $2,175.08 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 18 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,845 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F8 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on August 1, 2024 at prices ranging from $1,087.14 to $1,087.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $1,086.38 | $2,172.76 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 17 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,847 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F7 · price: Represents volume-weighted average price of sales of 2 shares of Company stock on August 1, 2024 at prices ranging from $1,086.36 to $1,086.40. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $1,085.71 | $3,257.13 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 16 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,849 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F6 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on August 1, 2024 at prices ranging from $1,085.60 to $1,085.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $1,084.71 | $3,254.13 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 15 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,852 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F5 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on August 1, 2024 at prices ranging from $1,084.15 to $1,084.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $1,083.57 | $1,083.57 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 14 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,855 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $1,082.17 | $1,082.17 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 13 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,856 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $1,080.06 | $1,080.06 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 12 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,857 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $1,076.07 | $3,228.21 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,858 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $1,074.34 | $1,074.34 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,861 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $1,073.03 | $1,073.03 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,862 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $1,070.46 | $4,281.84 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,863 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F4 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on August 1, 2024 at prices ranging from $1,070.42 to $1,070.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $1,068.08 | $1,068.08 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,867 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $1,067.53 | $1,067.53 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,868 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $1,066.33 | $4,265.32 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,869 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F3 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on August 1, 2024 at prices ranging from $1,066.01 to $1,066.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $1,065.39 | $6,392.34 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,873 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F2 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on August 1, 2024 at prices ranging from $1,065.04 to $1,065.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 1, 2024 at each separate price. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $1,062.71 | $1,062.71 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,879 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $1,058.90 | $1,058.90 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,880 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $1,053.22 | $1,053.22 |
DisclosureSEC source: 0001968202-24-000110 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,881 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $1,068.09 | $2,136.18 |
DisclosureSEC source: 0001968202-24-000105 · edgardoc.xml · nonDerivative · entry 19 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,882 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $1,067.51 | $3,202.53 |
DisclosureSEC source: 0001968202-24-000105 · edgardoc.xml · nonDerivative · entry 18 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,884 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F13 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on July 1, 2024 at prices ranging from $1,067.41 to $1,067.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2024 at each separate price. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $1,066.59 | $4,266.36 |
DisclosureSEC source: 0001968202-24-000105 · edgardoc.xml · nonDerivative · entry 17 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,887 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F12 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on July 1, 2024 at prices ranging from $1,066.31 to $1,066.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2024 at each separate price. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $1,065.52 | $3,196.56 |
DisclosureSEC source: 0001968202-24-000105 · edgardoc.xml · nonDerivative · entry 16 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,891 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F11 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on July 1, 2024 at prices ranging from $1,065.44 to $1,065.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2024 at each separate price. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $1,064.55 | $7,451.85 |
DisclosureSEC source: 0001968202-24-000105 · edgardoc.xml · nonDerivative · entry 15 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,894 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F10 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on July 1, 2024 at prices ranging from $1,064.18 to $1,064.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2024 at each separate price. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $1,063.87 | $5,319.35 |
DisclosureSEC source: 0001968202-24-000105 · edgardoc.xml · nonDerivative · entry 14 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,901 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F9 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on July 1, 2024 at prices ranging from $1,063.84 to $1,063.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2024 at each separate price. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 19 | $1,062.31 | $20,183.89 |
DisclosureSEC source: 0001968202-24-000105 · edgardoc.xml · nonDerivative · entry 13 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,906 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F8 · price: Represents volume-weighted average price of sales of 19 shares of Company stock on July 1, 2024 at prices ranging from $1,062.14 to $1,062.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2024 at each separate price. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $1,061.73 | $3,185.19 |
DisclosureSEC source: 0001968202-24-000105 · edgardoc.xml · nonDerivative · entry 12 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,925 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F7 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on July 1, 2024 at prices ranging from $1,061.69 to $1,061.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2024 at each separate price. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $1,060.14 | $3,180.42 |
DisclosureSEC source: 0001968202-24-000105 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,928 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $1,059.36 | $3,178.08 |
DisclosureSEC source: 0001968202-24-000105 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,931 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F6 · price: Represents volume-weighted average price of sales of 3 shares of Company stock on July 1, 2024 at prices ranging from $1,059.22 to $1,059.44. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2024 at each separate price. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 17 | $1,058.49 | $17,994.33 |
DisclosureSEC source: 0001968202-24-000105 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,934 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F5 · price: Represents volume-weighted average price of sales of 17 shares of Company stock on July 1, 2024 at prices ranging from $1,058.08 to $1,058.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2024 at each separate price. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $1,057.64 | $2,115.28 |
DisclosureSEC source: 0001968202-24-000105 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,951 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $1,056.81 | $2,113.62 |
DisclosureSEC source: 0001968202-24-000105 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,953 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $1,054.25 | $1,054.25 |
DisclosureSEC source: 0001968202-24-000105 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,955 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 8 | $1,053.60 | $8,428.80 |
DisclosureSEC source: 0001968202-24-000105 · edgardoc.xml · nonDerivative · entry 5 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,956 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F4 · price: Represents volume-weighted average price of sales of 8 shares of Company stock on July 1, 2024 at prices ranging from $1,053.32 to $1,053.70. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2024 at each separate price. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $1,052.19 | $6,313.14 |
DisclosureSEC source: 0001968202-24-000105 · edgardoc.xml · nonDerivative · entry 4 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,964 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F3 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on July 1, 2024 at prices ranging from $1,052.10 to $1,052.25. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2024 at each separate price. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $1,051.58 | $7,361.06 |
DisclosureSEC source: 0001968202-24-000105 · edgardoc.xml · nonDerivative · entry 3 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,970 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F2 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on July 1, 2024 at prices ranging from $1,051.03 to $1,051.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 1, 2024 at each separate price. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $1,050.87 | $2,101.74 |
DisclosureSEC source: 0001968202-24-000105 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,977 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 20:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $1,047.11 | $3,141.33 |
DisclosureSEC source: 0001968202-24-000105 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,979 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $1,000.04 | $5,000.20 |
DisclosureSEC source: 0001968202-24-000099 · edgardoc.xml · nonDerivative · entry 16 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,982 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F12 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on June 3, 2024 at prices ranging from $1,000.00 to $1,000.18. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 3, 2024 at each separate price. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $999.43 | $6,996.01 |
DisclosureSEC source: 0001968202-24-000099 · edgardoc.xml · nonDerivative · entry 15 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,987 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F11 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on June 3, 2024 at prices ranging from $999.14 to $999.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 3, 2024 at each separate price. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 14 | $998.44 | $13,978.16 |
DisclosureSEC source: 0001968202-24-000099 · edgardoc.xml · nonDerivative · entry 14 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,994 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F10 · price: Represents volume-weighted average price of sales of 14 shares of Company stock on June 3, 2024 at prices ranging from $998.08 to $998.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 3, 2024 at each separate price. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 15 | $997.76 | $14,966.40 |
DisclosureSEC source: 0001968202-24-000099 · edgardoc.xml · nonDerivative · entry 13 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,008 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F9 · price: Represents volume-weighted average price of sales of 15 shares of Company stock on June 3, 2024 at prices ranging from $997.02 to $997.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 3, 2024 at each separate price. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12 | $996.83 | $11,961.96 |
DisclosureSEC source: 0001968202-24-000099 · edgardoc.xml · nonDerivative · entry 12 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,023 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F8 · price: Represents volume-weighted average price of sales of 12 shares of Company stock on June 3, 2024 at prices ranging from $996.65 to $996.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 3, 2024 at each separate price. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $995.76 | $5,974.56 |
DisclosureSEC source: 0001968202-24-000099 · edgardoc.xml · nonDerivative · entry 11 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,035 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F7 · price: Represents volume-weighted average price of sales of 6 shares of Company stock on June 3, 2024 at prices ranging from $995.66 to $995.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 3, 2024 at each separate price. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $994.25 | $4,971.25 |
DisclosureSEC source: 0001968202-24-000099 · edgardoc.xml · nonDerivative · entry 10 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,041 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F6 · price: Represents volume-weighted average price of sales of 5 shares of Company stock on June 3, 2024 at prices ranging from $994.00 to $994.46. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 3, 2024 at each separate price. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 12 | $993.20 | $11,918.40 |
DisclosureSEC source: 0001968202-24-000099 · edgardoc.xml · nonDerivative · entry 9 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,046 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F5 · price: Represents volume-weighted average price of sales of 12 shares of Company stock on June 3, 2024 at prices ranging from $993.00 to $993.60. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 3, 2024 at each separate price. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7 | $992.19 | $6,945.33 |
DisclosureSEC source: 0001968202-24-000099 · edgardoc.xml · nonDerivative · entry 8 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,058 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F4 · price: Represents volume-weighted average price of sales of 7 shares of Company stock on June 3, 2024 at prices ranging from $992.00 to $992.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 3, 2024 at each separate price Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4 | $990.74 | $3,962.96 |
DisclosureSEC source: 0001968202-24-000099 · edgardoc.xml · nonDerivative · entry 7 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,065 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. F3 · price: Represents volume-weighted average price of sales of 4 shares of Company stock on June 3, 2024 at prices ranging from $990.54 to $990.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 3, 2024 at each separate price. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2 | $988.66 | $1,977.32 |
DisclosureSEC source: 0001968202-24-000099 · edgardoc.xml · nonDerivative · entry 6 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,069 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 7, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.